SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
SIGA Technologies Trading Down 0.2 %
Shares of SIGA Stock traded down $0.04 on Friday, reaching $24.75. The company's stock had a trading volume of 7,732,753 shares, compared to its average volume of 20,534,172. The stock's fifty day simple moving average is $14.68 and its 200-day simple moving average is $9.95. SIGA Technologies has a 1 year low of $5.84 and a 1 year high of $25.54. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of 25.78 and a beta of 0.63.
SIGA Technologies (NASDAQ:SIGA - Get Rating) last posted its earnings results on Thursday, August 4th. The company reported $0.03 earnings per share for the quarter. SIGA Technologies had a net margin of 48.67% and a return on equity of 48.79%. The firm had revenue of $16.67 million during the quarter. Equities research analysts forecast that SIGA Technologies will post 0.66 earnings per share for the current year.
Analysts Set New Price Targets
Separately, TheStreet lowered shares of SIGA Technologies from a "b" rating to a "c+" rating in a report on Monday, May 23rd.